New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: Synthesis and preliminary in vitro and in vivo biological properties

Journal of Controlled Release

Volumn 73, Issue 1, 2001, Pages 89-102

  Etrych, Tomáš ^a   Jelínková, Markéta ^b   Íhová, Blanka ^b   Ulbrich, Karel ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Doxorubicin; Drug carriers; Drug delivery; N (2 Hydroxypropyl)methacrylamide copolymers; pH sensitive linkage

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; DOXORUBICIN; DRUG CARRIER; HYDRAZINE DERIVATIVE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER DERIVATIVE; OLIGOPEPTIDE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DESIGN; DRUG EFFECT; DRUG HYDROLYSIS; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOSOME; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SPLEEN CELL; T CELL LYMPHOMA; TARGET CELL; TIMED DRUG RELEASE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; GLOBULINS; HYDROGEN-ION CONCENTRATION; LYMPHOMA, T-CELL; MALE; METHACRYLATES; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; OXIDATION-REDUCTION; T-LYMPHOCYTES;

EID: 0035907178     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00281-4     Document Type: Article

References (21)

1. Selective endocytosis of macromolecular drug carriers
2. Macromolecular prodrugs
3. Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A
4. Polymer conjugates with anticancer activity
5. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 carcinoma cells in vitro
6. Drug-polymer conjugates containing acid-cleavable bonds
7. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation
8. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action
9. Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells
10. Antibody directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting
11. Aminolyses of monomeric and polymeric 4-nitrophenyl esters of N-methacryloylated amino acids
12. Biocompatibility of N-2-(hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, and effect of heamatopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro
13. Biological properties of targetable poly[N-(2-hydroxypropyl)-methacrylamide] - Antibody conjugates
14. Studies on the rate and control of antibody oxidation by periodate
15. Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly-[2-(hydroxypropyl)methacrylamide] drug carriers in vitro and antitumour activity measured in vivo
16. Polymeric conjugates if drugs and antibodies for site-specific drug delivery
17. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B
18. Early phase tumour accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissue
19. Polymeric carriers of drugs for site-specific therapy
20. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene
21. 2-targeted conjugates and combined therapy with immunomodulators